​
​

Cardiol Therapeutics (CRDL) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CRDL Stock Forecast

Cardiol Therapeutics stock forecast is as follows: an average price target of $8.00 (represents a 330.11% upside from CRDL’s last price of $1.86) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

CRDL Price Target

The average price target for Cardiol Therapeutics (CRDL) is $8.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $8.00. This represents a potential 330.11% upside from CRDL's last price of $1.86.

CRDL Analyst Ratings

Buy

According to 3 Wall Street analysts, Cardiol Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CRDL stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cardiol Therapeutics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 23, 2024Edward NashCanaccord Genuity$8.00$2.24257.14%330.11%
Row per page
Go to

The latest Cardiol Therapeutics stock forecast, released on May 23, 2024 by Edward Nash from Canaccord Genuity, set a price target of $8.00, which represents a 257.14% increase from the stock price at the time of the forecast ($2.24), and a 330.11% increase from CRDL last price ($1.86).

Cardiol Therapeutics Price Target by Period

1M3M12M
# Anlaysts--1
Avg Price Target--$8.00
Last Closing Price$1.86$1.86$1.86
Upside/Downside-100.00%-100.00%330.11%

In the current month, the average price target of Cardiol Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cardiol Therapeutics's last price of $1.86. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 24, 2024H.C. WainwrightBuyBuyHold
Jun 26, 2024B. Riley-BuyInitialise
May 23, 2024Canaccord GenuityBuyBuyHold
Row per page
Go to

Cardiol Therapeutics's last stock rating was published by H.C. Wainwright on Oct 24, 2024. The company gave CRDL a "Buy" rating, the same as its previous rate.

Cardiol Therapeutics Financial Forecast

Cardiol Therapeutics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
# Analysts-----------
Surprise %-----------

Cardiol Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRDL's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Cardiol Therapeutics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EBITDA-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

undefined analysts predict CRDL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Cardiol Therapeutics's previous annual EBITDA (undefined) of $NaN.

Cardiol Therapeutics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
Net Income-----------
Avg Forecast$-5.89M$-5.40M$-5.40M$-4.91M$-4.91M$-5.40M$-4.91M$-4.91M$-6.03M$-6.48M$-7.11M
High Forecast$-5.89M$-5.40M$-5.40M$-4.91M$-4.91M$-5.40M$-4.91M$-4.91M$-6.03M$-5.18M$-7.11M
Low Forecast$-5.89M$-5.40M$-5.40M$-4.91M$-4.91M$-5.40M$-4.91M$-4.91M$-6.03M$-7.12M$-7.11M
Surprise %-----------

Cardiol Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRDL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cardiol Therapeutics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
SG&A-----------
Avg Forecast-----------
High Forecast-----------
Low Forecast-----------
Surprise %-----------

Cardiol Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRDL last annual SG&A of $NaN (undefined).

Cardiol Therapeutics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-----------
EPS-----------
Avg Forecast$-0.09$-0.08$-0.08$-0.07$-0.07$-0.08$-0.07$-0.07$-0.09$-0.09$-0.10
High Forecast$-0.09$-0.08$-0.08$-0.07$-0.07$-0.08$-0.07$-0.07$-0.09$-0.08$-0.10
Low Forecast$-0.09$-0.08$-0.08$-0.07$-0.07$-0.08$-0.07$-0.07$-0.09$-0.10$-0.10
Surprise %-----------

According to undefined Wall Street analysts, Cardiol Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRDL previous annual EPS of $NaN (undefined).

Cardiol Therapeutics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
FLGCFlora Growth$1.31$173.5013144.27%Hold
CRDLCardiol Therapeutics$1.86$8.00330.11%Buy

CRDL Forecast FAQ

Is Cardiol Therapeutics a good buy?

Yes, according to 3 Wall Street analysts, Cardiol Therapeutics (CRDL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CRDL's total ratings.

What is CRDL's price target?

Cardiol Therapeutics (CRDL) average price target is $8 with a range of $8 to $8, implying a 330.11% from its last price of $1.86. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cardiol Therapeutics stock go up soon?

According to Wall Street analysts' prediction for CRDL stock, the company can go up by 330.11% (from the last price of $1.86 to the average price target of $8), up by 330.11% based on the highest stock price target, and up by 330.11% based on the lowest stock price target.

Can Cardiol Therapeutics stock reach $3?

CRDL's average twelve months analyst stock price target of $8 supports the claim that Cardiol Therapeutics can reach $3 in the near future.

What are Cardiol Therapeutics's analysts' financial forecasts?

Cardiol Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.134M (high $-20.134M, low $-20.134M), average SG&A $0 (high $0, low $0), and average EPS is $-0.293 (high $-0.293, low $-0.293). CRDL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-21.607M (high $-21.607M, low $-21.607M), average SG&A $0 (high $0, low $0), and average EPS is $-0.314 (high $-0.314, low $-0.314).